Osteoporosis International

, Volume 21, Issue 7, pp 1277–1285

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial

  • R. Eastell
  • T. Lang
  • S. Boonen
  • S. Cummings
  • P. D. Delmas
  • J. A. Cauley
  • Z. Horowitz
  • E. Kerzberg
  • G. Bianchi
  • D. Kendler
  • P. Leung
  • Z. Man
  • P. Mesenbrink
  • E. F. Eriksen
  • D. M. Black
  • for the HORIZON Pivotal Fracture Trial
Original Article

Abstract

Summary

Changes in bone mineral density and bone strength following treatment with zoledronic acid (ZOL) were measured by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA). ZOL treatment increased spine and hip BMD vs placebo, assessed by QCT and DXA. Changes in trabecular bone resulted in increased bone strength.

Introduction

To investigate bone mineral density (BMD) changes in trabecular and cortical bone, estimated by quantitative computed analysis (QCT) or dual-energy X-ray absorptiometry (DXA), and whether zoledronic acid 5 mg (ZOL) affects bone strength.

Methods

In 233 women from a randomized, controlled trial of once-yearly ZOL, lumbar spine, total hip, femoral neck, and trochanter were assessed by DXA and QCT (baseline, Month 36). Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) were evaluated.

Results

Mean between-treatment differences for lumbar spine BMD were significant by DXA (7.0%, p < 0.01) and QCT (5.7%, p < 0.0001). Between-treatment differences were significant for trabecular spine (p = 0.0017) [non-parametric test], trabecular trochanter (10.7%, p < 0.0001), total hip (10.8%, p < 0.0001), and compressive strength indices at femoral neck (8.6%, p = 0.0001), and trochanter (14.1%, p < 0.0001).

Conclusions

Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.

Keywords

Bisphosphonates Bone densitometry Bone QCT Clinical trials Osteoporosis 

References

  1. 1.
    Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMedGoogle Scholar
  2. 2.
    Cheng X, Li J, Lu Y, Keyak J, Lang T (2007) Proximal femoral density and geometry measurements by quantitative computed tomography: association with hip fracture. Bone 40:169–174CrossRefPubMedGoogle Scholar
  3. 3.
    Lang T, Leblanc A, Evans H, Lu Y, Genant H, Yu A (2004) Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res 19:1006–1012CrossRefPubMedGoogle Scholar
  4. 4.
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215CrossRefPubMedGoogle Scholar
  5. 5.
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ (2005) One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565CrossRefPubMedGoogle Scholar
  6. 6.
    McClung MR, San MJ, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF (2005) Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762–1768CrossRefPubMedGoogle Scholar
  7. 7.
    Genant HK, Lang T, Fuerst T, Pinette KV, Zhou C, Thiebaud D, Diez-Perez A (2004) Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. Bone 35:1164–1168CrossRefPubMedGoogle Scholar
  8. 8.
    Lotz JC, Hayes WC (1990) The use of quantitative computed tomography to estimate risk of fracture of the hip from falls. J Bone Joint Surg Am 72:689–700PubMedGoogle Scholar
  9. 9.
    Buckley JM, Loo K, Motherway J (2007) Comparison of quantitative computed tomography-based measures in predicting vertebral compressive strength. Bone 40:767–774CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  • R. Eastell
    • 1
    • 16
  • T. Lang
    • 2
  • S. Boonen
    • 3
  • S. Cummings
    • 4
  • P. D. Delmas
    • 5
  • J. A. Cauley
    • 6
  • Z. Horowitz
    • 7
  • E. Kerzberg
    • 8
  • G. Bianchi
    • 9
  • D. Kendler
    • 10
  • P. Leung
    • 11
  • Z. Man
    • 12
  • P. Mesenbrink
    • 13
  • E. F. Eriksen
    • 14
  • D. M. Black
    • 15
  • for the HORIZON Pivotal Fracture Trial
  1. 1.Academic Unit of Bone MetabolismUniversity of SheffieldSheffieldUK
  2. 2.Department of RadiologyUniversity of CaliforniaSan FranciscoUSA
  3. 3.Leuven University Centre for Metabolic Bone Diseases and Division of Geriatric MedicineKatholieke Universiteit LeuvenLeuvenBelgium
  4. 4.CPMC Research InstituteUniversity of CaliforniaSan FranciscoUSA
  5. 5.INSERM Research Unit 831 and University of LyonLyonFrance
  6. 6.Department of EpidemiologyUniversity of PittsburghPittsburghUSA
  7. 7.Savient PharmaceuticalsNew JerseyUSA
  8. 8.Argentine Reference Center in OsteoporosisHospital Ramos MejíaBuenos AiresArgentina
  9. 9.Division of RheumatologyLa Colletta HospitalGenoaItaly
  10. 10.Osteoporosis Research CentreVancouverCanada
  11. 11.Faculty of MedicineChinese University of Hong Kong, Prince of Wales HospitalHong KongChina
  12. 12.Centro TIEMPOUniversidad FavaloroBuenos AiresArgentina
  13. 13.Novartis Pharmaceuticals CorporationNew JerseyUSA
  14. 14.Department of EndocrinologyAker University HospitalOsloNorway
  15. 15.Department of Epidemiology and BiostatisticsUniversity of CaliforniaSan FranciscoUSA
  16. 16.Metabolic Bone CentreSorby Wing, Northern General HospitalSheffieldUK

Personalised recommendations